Olema Oncology names Jason O'Byrne as chief financial officer
The appointment, effective August 11, 2026, comes as the company approaches pivotal data from its OPERA-01 trial and prepares for a potential first commercial launch.
SEC filing
Latest
2 stories
Thursday, August 13
Monday, August 10
Olema completes OPERA-01 enrollment, pushes top-line data to Q1 2027
Olema Oncology also struck a Bayer collaboration testing its KAT6 inhibitor with darolutamide in prostate cancer and ended the quarter with $461.1 million in cash.
SEC filing